Apr 30, 2026 08:00AM
Mar 30, 2026 01:00PM
Mar 30, 2026 01:00PM
Mar 24, 2026 07:30AM
Mar 24, 2026 07:30AM
Mar 10, 2026 08:00AM
Feb 19, 2026 08:30AM Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
Feb 12, 2026 08:00AM
Dec 21, 2025 04:00AM
Dec 17, 2025 08:02AM
Dec 17, 2025 08:00AM
Nov 8, 2025 04:57PM
Nov 8, 2025 04:57PM
Oct 30, 2025 08:00AM Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress
Oct 10, 2025 06:40AM
Oct 1, 2025 07:30AM
Oct 1, 2025 07:30AM
Sep 29, 2025 06:58PM
Sep 28, 2025 11:13AM
Sep 28, 2025 11:13AM
Sep 28, 2025 11:13AM New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran
Aug 30, 2025 04:00PM
Aug 30, 2025 10:30AM
Aug 30, 2025 10:30AM
Aug 30, 2025 10:30AM
Aug 30, 2025 10:30AM
Aug 30, 2025 10:30AM
Aug 30, 2025 10:30AM Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial
Aug 30, 2025 10:30AM
Aug 11, 2025 08:00AM
Jul 31, 2025 08:00AM
Jun 9, 2025 06:00AM
Jun 9, 2025 06:00AM
May 17, 2025 05:50AM
May 1, 2025 08:00AM Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress
Apr 28, 2025 08:00AM
Apr 28, 2025 08:00AM
Apr 12, 2025 04:00AM
Apr 11, 2025 09:44AM
Apr 10, 2025 05:32AM
Mar 31, 2025 05:21AM
Mar 29, 2025 01:00PM Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology’s Annual Scientific Sess
Mar 28, 2025 04:45PM
Mar 28, 2025 04:44PM
Mar 24, 2025 08:58AM
Mar 24, 2025 06:43AM
Mar 21, 2025 07:44AM
Mar 21, 2025 06:56AM
Mar 21, 2025 06:46AM Alnylam Pharmaceuticals (ALNY) PT Raised to $390 at Canaccord Genuity
Mar 20, 2025 05:57PM

325,552 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All